Back to search

Article

A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis

2023-08-20

Abstract excerpt

<h4>Background</h4> There is increasing evidence that Epstein-Barr virus (EBV) plays a causal role in MS. No treatments have been shown to reduce EBV turnover. We studied the effect of famciclovir on salivary EBV shedding in people with MS ( NCT05283551 ). <h4>Methods</h4> People with MS receiving natalizumab provided weekly saliva samples for 12 weeks before starting Famciclovir 500mg bd. 12 saliva samples were p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6ca7d086-1c3d-5916-8853-61763680e485
DOI
10.1101/2023.08.18.23294265
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple SclerosisDOI 10.1101/2023.08.18.23294265
Select a neighboring publication to make it the new centre.